9/18/2013

The FDA granted priority-review status to GlaxoSmithKline's application to market a combination of Tafinlar, or dabrafenib, and Mekinist, or trametinib, for treatment of metastatic melanoma with the BRAF V600E or V600K mutation. A decision could come soon after the new year.

Full Story:
PharmaTimes (U.K.)

Related Summaries